HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a $25 price target.

July 01, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Milestone Pharmaceuticals and maintained a $25 price target, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $25 price target by HC Wainwright & Co. suggests strong confidence in Milestone Pharmaceuticals' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100